Assessment of the presence of extended-spectrum beta-lactamase-producing Escherichia coli in eggshells and ready-to-eat products

Egea, Pilar; López-Cerero, Lorena; Navarro, M.D.; Pascual, Álvaro

doi:10.1007/s10096-011-1168-3

Cited by 25 publications

(21 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results were observed in vegetables collected in South Korea (Kim et al, 2015), salads in the Netherlands (Reuland et al, 2014), and Spain (Egea et al, 2011), displaying a new route of introduction for ESBLs and pathogenic Enterobacteriaceae.…”

Section: Expansion Toward New Ecological Nichessupporting

confidence: 72%

A Review of SHV Extended-Spectrum β-Lactamases: Neglected Yet Ubiquitous

2016

View full text Add to dashboard Cite

β-lactamases are the primary cause of resistance to β-lactams among members of the family Enterobacteriaceae. SHV enzymes have emerged in Enterobacteriaceae causing infections in health care in the last decades of the Twentieth century, and they are now observed in isolates in different epidemiological settings both in human, animal and the environment. Likely originated from a chromosomal penicillinase of Klebsiella pneumoniae, SHV β-lactamases currently encompass a large number of allelic variants including extended-spectrum β-lactamases (ESBL), non-ESBL and several not classified variants. SHV enzymes have evolved from a narrow- to an extended-spectrum of hydrolyzing activity, including monobactams and carbapenems, as a result of amino acid changes that altered the configuration around the active site of the β -lactamases. SHV-ESBLs are usually encoded by self-transmissible plasmids that frequently carry resistance genes to other drug classes and have become widespread throughout the world in several Enterobacteriaceae, emphasizing their clinical significance.

show abstract

Section: Expansion Toward New Ecological Nichessupporting

confidence: 72%

A Review of SHV Extended-Spectrum β-Lactamases: Neglected Yet Ubiquitous

2016

View full text Add to dashboard Cite

show abstract

“…This may be provoked by excessive use of antimicrobials in medical practice but also by the widespread contamination of the food chain with ESBL Enterobacteriaceae , which is also the case in countries with – until now – no extreme resistance problems, such as Denmark. [30–32] Data from India indicate that more than half of all E. coli strains and about one-third of Klebsiella strains isolated from IAI produce ESBL. [33] Data from Hawser et al[33] show important differences in resistance rates for E. coli and Klebsiella species among European countries, albeit that the study is unclear about the origin of infection (either community or hospital onset).…”

Section: Antimicrobial Therapymentioning

confidence: 99%

Essentials for Selecting Antimicrobial Therapy for Intra-Abdominal Infections

Blot

Waele

Vogelaers

2012

Drugs

View full text Add to dashboard Cite

Intra-abdominal infection (IAI) is a complex disease entity in which different aspects must be balanced in order to select the proper antimicrobial regimen and determine duration of therapy. A current classification indicates different faces of peritonitis. Primary peritonitis implies an intact gastrointestinal tract without overt barrier disruption. Secondary peritonitis refers to localized or diffuse peritoneal inflammation and abscess formation due to disruption of the anatomical barrier. Tertiary peritonitis includes cases that cannot be solved by a single or even sequential surgical intervention, often in combination with sequential courses of antimicrobial therapy. The most frequently used classification distinguishes ‘uncomplicated’ and ‘complicated’ IAI. In uncomplicated IAI, the infectious process is contained within a single organ, without anatomical disruption. In complicated IAI, disease is extended, with either localized or generalized peritonitis. However, there exists more than a single dimension of complexity in IAI, including severity of disease expression through systemic inflammation. As the currently used classifications of IAI often incite confusion by mixing elements of anatomical barrier disruption, severity of disease expression and (the likelihood of) resistance involvement, we propose an alternative for the current widely accepted classification. We suggest abandoning the terms ‘uncomplicated’ and ‘complicated’ IAI, as they merely confuse the issue. Furthermore, the term ‘tertiary peritonitis’ should likewise be discarded, as this simply refers to treatment failure of secondary peritonitis resulting in a state of persistent infection and/or inflammation. Hence, anatomical disruption and disease severity should be separated into different phenotypes for the same disease in combination with either presence or absence of risk factors for involvement of pathogens that are not routinely covered in first-line antimicrobial regimens (Pseudomonas aeruginosa, enterococci, Candida species and resistant pathogens). Generally, these risk factors can be brought back to recent exposure to antimicrobial agents and substantial length of stay in healthcare settings (5–7 days). As such, we developed a grid based on the different components of the classification: (i) anatomical disruption; (ii) severity of disease expression; and (iii) either community-acquired/early-onset healthcare-associated origin or healthcare-associated origin and/or recent antimicrobial exposure. The grid allows physicians to define the index case of IAI in a more unequivocal way and to select the most convenient empirical antimicrobial regimens. The grid advises on the necessity of covering nosocomial Gram-negative bacteria (including P. aeruginosa), enterococci and yeasts. The basis of antimicrobial therapy for IAI is that both Gram-negative and anaerobic bacteria should always be covered.In recent years, some newer agents such as doripenem, moxifloxacin and tigecycline have been added to the antimicrobial armamentarium for IAI. F...

show abstract

“…ESBL/AmpC-producing isolates can be found in nearly all food-producing animals [8], on all kinds of meats sold at retail [9], [10], [11] and in vegetables [12]. A high prevalence of ESBL/AmpC producing isolates is found in broilers and on broiler meat [9], [13], [14], [15].…”

Section: Introductionmentioning

confidence: 99%

Presence of ESBL/AmpC -Producing Escherichia coli in the Broiler Production Pyramid: A Descriptive Study

Dierikx

Goot

Smith³

et al. 2013

PLoS ONE

181

162

View full text Add to dashboard Cite

Broilers and broiler meat products are highly contaminated with extended spectrum beta-lactamase (ESBL) or plasmid-mediated AmpC beta-lactamase producing Escherichia coli and are considered to be a source for human infections. Both horizontal and vertical transmission might play a role in the presence of these strains in broilers. As not much is known about the presence of these strains in the whole production pyramid, the epidemiology of ESBL/AmpC-producing E. coli in the Dutch broiler production pyramid was examined. Cloacal swabs of Grandparent stock (GPS) birds (one−/two-days (breed A and B), 18 and 31 weeks old (breed A)), one-day old Parent stock birds (breed A and B) and broiler chickens of increasing age (breed A) were selectively cultured to detect ESBL/AmpC-producing isolates. ESBL/AmpC-producing isolates were found at all levels in the broiler production pyramid in both broiler breeds examined. Prevalence was already relatively high at the top of the broiler production pyramid. At broiler farms ESBL/AmpC producing E. coli were still present in the environment of the poultry house after cleaning and disinfection. Feed samples taken in the poultry house also became contaminated with ESBL/AmpC producing E. coli after one or more production weeks. The prevalence of ESBL/AmpC-positive birds at broiler farms increased within the first week from 0–24% to 96–100% independent of the use of antibiotics and stayed 100% until slaughter. In GPS breed A, prevalence at 2 days, 18 weeks and 31 weeks stayed below 50% except when beta-lactam antibiotics were administered. In that case prevalence increased to 100%. Interventions minimizing ESBL/AmpC contamination in broilers should focus on preventing horizontal and vertical spread, especially in relation to broiler production farms.

show abstract

Assessment of the presence of extended-spectrum beta-lactamase-producing Escherichia coli in eggshells and ready-to-eat products

Cited by 25 publications

References 24 publications

A Review of SHV Extended-Spectrum β-Lactamases: Neglected Yet Ubiquitous

A Review of SHV Extended-Spectrum β-Lactamases: Neglected Yet Ubiquitous

Essentials for Selecting Antimicrobial Therapy for Intra-Abdominal Infections

Presence of ESBL/AmpC -Producing Escherichia coli in the Broiler Production Pyramid: A Descriptive Study

Contact Info

Product

Resources

About